Alcami Corporation

Alcami Corporation

Recent Posts by Alcami Corporation:

Special Feature Editorial: Outsourcing Analytical Testing - Novel Services Elicit Consistent, Quantifiable, & Faster Results

Michael Freeman, associate director and business unit head for lab services at Alcami, recently contributed to an article in Drug Development & Delivery titled Outsourcing Analytical Testing: Novel Services Elicit Consistent, Quantifiable, & Faster Results. In the article, Freeman explains how Alcami's end-to-end analytical testing platform supports client programs through every stage of a product's lifecycle, from early phase development activities to commercial support for both small and large molecule products.


Topics: Editorials Analytical Testing Analytical Development

Editorial: High-Potency APIs -- Engineered for Safety

Mark Millar, director and business unit head for API at Alcami, recently participated in the high-potency APIs section of Speciality Chemicals Magazine. The write-up goes in-depth about investments being made in the high-potency API market and provides an overview into occupational health and safety challenges in manufacturing.

Topics: HPAPI Editorials

The Benefits of Establishing a Full-Time Equivalent (FTE) Program with Your Contract Service Provider

A Full-Time Equivalent (FTE) agreement is a comprehensive analytical service that grants pharmaceutical and biotech companies the flexibility, freedom, and consistent control of their outsourced laboratory programs. In this article, we will discuss the benefits of establishing a FTE program with an outsourcing partner and examine the customized solutions that are available for a broad spectrum of testing needs.

Alcami’s Extended Workbench offering is a FTE program tailored to your specific needs. An Extended Workbench program can vary in size, management approach, and scope, and is available across any pharmaceutical platform, from small molecule API to biologic drug product. 

Topics: Analytical Testing Blogs

Alcami Expands its Sterile Fill-Finish Capacity with Acquisition of TriPharm Services

Transaction Advances Alcami’s Strategic Plan by Adding Scale in Attractive and Growing Parenteral Markets

Alcami Investors Make Additional Equity Investment Alongside Ampersand Capital Partners to Fund Expansion

Durham, NC (USA) – January 17, 2020 – Alcami Corporation (“Alcami”), a leading provider of fully-integrated custom end-to-end solutions for the pharmaceutical and biologics industries, today announced it has acquired TriPharm Services (“TriPharm”), a new state-of-the-art sterile fill-finish manufacturing center located near Research Triangle Park, North Carolina. The acquisition of TriPharm follows the recently announced $17 million expansion of Alcami’s sterile fill-finish facility in Charleston, South Carolina.

Topics: Company News Parenteral Manufacturing

Schedule a Meeting with Alcami at PharmSci 360

Alcami will be exhibiting at AAPS 2019 PharmSci 360, to be held November 3 - 6 in San Antonio, Texas. Schedule a meeting or stop by booth #1511 to connect with our team.

Schedule a Meeting
Topics: Events

Schedule a Meeting with Alcami at CPhI WW in Frankfurt

Alcami will be exhibiting at CPhI Worldwide, to be held November 5 - 7 in Frankfurt, Germany. Schedule a meeting or stop by booth #121C31 to connect with our team.

Topics: Events

Case Study: Abeona Therapeutics

Abeona Therapeutics, Inc. is a fully-integrated gene and cell therapy company at the forefront of the rapidly-advancing field of genetic medicine. Their late-stage candidate, EB-101, is an autologous, ex-vivo, gene-corrected cell therapy poised to enter a Phase 3 clinical trial for Recessive Dystrophic Epidermolysis Bullosa (RDEB).

Read this case study to learn how Alcami's extensive experience with small and large molecule development services, regulatory compliance, and specialty techniques helped

Topics: Regulatory Compliance Biologics Analytical Testing Analytical Development Orphan Drugs Case Study

Alcami Exhibiting at BIO International Convention 2019

Alcami will be attending BIO International Convention, to be held June 3 - 6, 2019 in Philadelphia, PA.

Be sure to stop by Booth #3401 and connect with the Alcami team.

Schedule a Meeting


Topics: Events


Name: Bhadresh Nayee
Alcami Site: Edison, NJ

How long have you been with Alcami?
I have been with Alcami since 2007.

What is your role? 
I’m working as a microbiology analyst at our Edison, New Jersey site. My day-to-day activities involve antibiotic testing, container closure integrity testing, and isolating/creating cultures of bacteria to study the impact of these microorganisms in order to obtain information on types and levels of microbial contamination.

What is the most rewarding part of your job?
The most rewarding part of my job is our clients' satisfaction from my work.

Topics: Alcami in Action

Editorial: Overcoming the Opioid Overdose Crisis

Alcami recently contributed to an article in the Greater Wilmington Business Journal titled, "Overcoming the Opioid Overdose Crisis."

Our community has come together, like many others, to combat the opioid crisis. Several local agencies have rallied to create impactful community resources. A 2016 survey by Castlight, which listed Wilmington, NC as the #1 city for opioid abuse in the United States, was a wake-up call to the level of severity this community has been affected by opioid-related fatalities and hardships. At Alcami, we work with our clients to develop abuse deterrence medicines to help combat this nationwide epidemic that hits home, even here in Wilmington.

Topics: Abuse-Deterrence Editorials